Effect of a multifactorial intervention on mortality in type 2 diabetes.

BACKGROUND Intensified multifactorial intervention - with tight glucose regulation and the use of renin-angiotensin system blockers, aspirin, and lipid-lowering agents - has been shown to reduce the risk of nonfatal cardiovascular disease among patients with type 2 diabetes mellitus and microalbuminuria. We evaluated whether this approach would have an effect on the rates of death from any cause and from cardiovascular causes. METHODS In the Steno-2 Study, we randomly assigned 160 patients with type 2 diabetes and persistent microalbuminuria to receive either intensive therapy or conventional therapy; the mean treatment period was 7.8 years. Patients were subsequently followed observationally for a mean of 5.5 years, until December 31, 2006. The primary end point at 13.3 years of follow-up was the time to death from any cause. RESULTS Twenty-four patients in the intensive-therapy group died, as compared with 40 in the conventional-therapy group (hazard ratio, 0.54; 95% confidence interval [CI], 0.32 to 0.89; P=0.02). Intensive therapy was associated with a lower risk of death from cardiovascular causes (hazard ratio, 0.43; 95% CI, 0.19 to 0.94; P=0.04) and of cardiovascular events (hazard ratio, 0.41; 95% CI, 0.25 to 0.67; P<0.001). One patient in the intensive-therapy group had progression to end-stage renal disease, as compared with six patients in the conventional-therapy group (P=0.04). Fewer patients in the intensive-therapy group required retinal photocoagulation (relative risk, 0.45; 95% CI, 0.23 to 0.86; P=0.02). Few major side effects were reported. CONCLUSIONS In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes. (ClinicalTrials.gov number, NCT00320008.)

[1]  R. Holman,et al.  Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75) , 2006, Diabetologia.

[2]  M. Harris,et al.  Diabetes and decline in heart disease mortality in US adults. , 1999, JAMA.

[3]  O. Pedersen,et al.  Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  Stephen J. Aldington,et al.  Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study , 1995, Diabetologia.

[5]  E. Barrett-Connor,et al.  Chapter 19 Heart Disease and Diabetes , 2022 .

[6]  B. Carstensen Regression models for interval censored survival data: application to HIV infection in Danish homosexual men. , 1996, Statistics in medicine.

[7]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[8]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[9]  O. Pedersen,et al.  Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. , 2003, Metabolism: clinical and experimental.

[10]  O. Pedersen,et al.  Target intervention against multiple‐risk markers to reduce cardiovascular disease in patients with type 2 diabetes , 2004, Annals of medicine.

[11]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[12]  O. Pedersen,et al.  Multi-targeted and aggressive treatment of patients with type 2 diabetes at high risk: what are we waiting for? , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[13]  B. Richelsen,et al.  Type 2-diabetes og det metaboliske syndrom - diagnostik og behandling , 2000 .

[14]  J. Laragh,et al.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial , 2004, The Lancet.

[15]  V. Basevi Standards of medical care in diabetes--2007. , 2009, Diabetes care.

[16]  Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial , 2022 .

[17]  L. Balant,et al.  The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. , 1982, Kidney international.

[18]  O. Pedersen,et al.  Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria , 2004, Diabetologia.

[19]  H. Parving,et al.  Albuminuria and Poor Glycemic Control Predict Mortality in NIDDM , 1995, Diabetes.

[20]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[21]  R. Collins,et al.  Heart Protection Study , 2003, The Lancet.

[22]  R. Holman,et al.  Erratum: The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56) (Clinical Science (2001) 101 (671-679)) , 2002 .

[23]  B. Brenner,et al.  Dialysis delayed is death prevented: a clinical perspective on the RENAAL study. , 2003, Kidney international.

[24]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[25]  David Colquhoun,et al.  Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up , 2002, The Lancet.

[26]  K. Juel,et al.  The Danish registers of causes of death. , 1999, Danish medical bulletin.

[27]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[28]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[29]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[30]  O. Pedersen,et al.  Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. , 2004, Diabetes.

[31]  P. Macfarlane,et al.  Long-term follow-up of the West of Scotland Coronary Prevention Study. , 2007, The New England journal of medicine.

[32]  M. Fisher Heart Disease and Diabetes , 2009 .

[33]  S. Saydah,et al.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes , 2004 .

[34]  P. Gæde Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: rationale and effect on late-diabetic complications , 2006 .

[35]  G. Moneta,et al.  Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes , 2007 .

[36]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.

[37]  R. Holman,et al.  The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.

[38]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[39]  F. McAlister,et al.  Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis , 2004, Canadian Medical Association Journal.

[40]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[41]  S. Yusuf Two decades of progress in preventing vascular disease , 2002, The Lancet.